VYNE Therapeutics Inc. (VYNE): Price and Financial Metrics

VYNE Therapeutics Inc. (VYNE): $2.58

0.05 (-1.90%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add VYNE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#203 of 360

in industry

VYNE Price/Volume Stats

Current price $2.58 52-week high $7.48
Prev. close $2.63 52-week low $1.67
Day low $2.51 Volume 22,600
Day high $2.65 Avg. volume 104,003
50-day MA $2.62 Dividend yield N/A
200-day MA $2.95 Market Cap 37.48M

VYNE Stock Price Chart Interactive Chart >


VYNE Therapeutics Inc. (VYNE) Company Bio


VYNE Therapeutics Inc. operates as a clinical stage bio-pharmaceutical company. The Company develops medicines and therapies for the treatment of chronic pruritus and cough. VYNE Therapeutics serves customers worldwide.


VYNE Latest News Stream


Event/Time News Detail
Loading, please wait...

VYNE Latest Social Stream


Loading social stream, please wait...

View Full VYNE Social Stream

Latest VYNE News From Around the Web

Below are the latest news stories about VYNE THERAPEUTICS INC that investors may wish to consider to help them evaluate VYNE as an investment opportunity.

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025 Phase 2b preparatory activities progressing for VYN201 in nonsegmental vitiligo following positive Phase 1b results On track for VYN202 IND submission by year-end 2023, with plans to begin Phase 1a trial in Q1 2024 BRIDGEWATER, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage bi

Yahoo | November 13, 2023

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans Program to feature KOL presentation covering unmet need and current treatment landscape in vitiligo BRIDGEWATER, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today an

Yahoo | November 7, 2023

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Transformative capital raise to fund VYNE’s BET inhibitor programs through the end of 2025BRIDGEWATER, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the closing of its previously announced private placement financing (the “PIPE”). In the PIPE, VYNE received aggrega

Yahoo | November 1, 2023

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritisFollowing completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinical trial in Q1 2024, followed by Phase 1b trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024Preclinical data and clinical programs to be discussed at

Yahoo | October 30, 2023

VYNE Therapeutics Announces Private Placement of $88 Million

Transaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare

Yahoo | October 30, 2023

Read More 'VYNE' Stories Here

VYNE Price Returns

1-mo 4.45%
3-mo 14.16%
6-mo -35.01%
1-year -60.91%
3-year -96.05%
5-year -99.47%
YTD 10.73%
2023 -13.70%
2022 -85.29%
2021 -83.86%
2020 -65.95%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!